-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

703A.O1.6 703. Cellular Immunotherapies: Basic and Translational III

Symposia: Cellular Immunotherapies: Basic and Translational Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, ALL, Lymphoid Leukemias, Biological therapies, Fundamental Science, Translational Research, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, T Cell lymphoma, Diseases, Gene Therapy, Immune Disorders, immunodeficiency, Therapies, Immunotherapy, Lymphoid Malignancies, Adverse Events, metabolism, Biological Processes, Natural Killer (NK) Cell Therapies, Technology and Procedures, gene editing, Transplantation
Monday, December 12, 2022: 4:30 PM-6:00 PM
La Nouvelle Orleans Ballroom C (Ernest N. Morial Convention Center)
Melody Smith, MD, MS, Memorial Sloan-Kettering Cancer Center and Stephan Mielke, MD, Karolinska Institutet and University Hospital, Karolinska Comprehensive Cancer Center
Mielke: DNA Prime SA: Other: via my institution, Speakers Bureau; Miltenyi: Other: DSMB via my institution; Immunicum/Mendus: Other: DSMB via my institution; KITE/GILEAD: Other: Expert Panel with travel costs; via my institution; Novartis: Other: via my institution, Speakers Bureau; Celgene/BMS: Other: via my institution, Speakers Bureau; Janssen: Other: via my institution, Speakers Bureau; SWECARNET: Membership on an entity's Board of Directors or advisory committees, Other: via my institution.
This session focuses on future CAR T cell therapies at their early stage of translational development but with a clear link to the clinic such as unmet medical need (for example in T-ALL). Focus is on the improvement of CAR T cell therapy by increasing fitness and persistence as well as enhancing anti-tumor effects of gene-modified effector cells in animal models. This contains novel mechanistic insights in antigen-engagement and the role of co-stimulation and even mitochondria and opens new fascinating perspectives such as the use of regulatory CAR T cells and advanced off-the shelf treatment strategies.
4:30 PM

David Granadier, BS1*, Kirsten Cooper2*, Sinéad Kinsella, MSc, PhD1, Cindy Evandy3*, Lorenzo Iovino, MD, PhD4, Paul DeRoos2*, Steve Shannon-Sevillano1*, Dante Denny Acenas, BS1* and Jarrod A Dudakov, PhD2

1Fred Hutchinson Cancer Research Center, Seattle, WA
2Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
3Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
4Hematology Division, AOUP, Seattle, WA

4:45 PM

Shinpei Harada1*, Daigo Hashimoto, MD2, Hajime Senjo, M.D.2, Kazuki Yoneda, M.D.2*, Zixuan Zhang2*, Xuanzhong Chen2*, Ryo Kikuchi, M.D.2*, Masahiro Chiba, M.D.2*, Hiroyuki Ohigashi, M.D., Ph.D.2*, Takahide Ara, M.D., Ph.D.2*, Masao Nakagawa, M.D., Ph.D.2, Masashi Suganuma, M.D., Ph.D.3*, Rick C. Tsai, M.D., D.M.D.3* and Takanori Teshima, M.D., Ph.D.2

1Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo City, Japan
2Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan
3LUCA Science Inc., Tokyo, Japan

5:00 PM

Xing Fah Alex Wong1*, Josie Ng1*, Simin Zheng1*, Rizal Ismail1*, Hongliang Qian1*, Dario Campana2 and Ying Xim Tan3

1MediSix Therapeutics, Singapore, Singapore
2Department of Pediatrics and Cancer Science Institute, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
3Medisix Therapeutics, Singapore, Singapore

5:15 PM

Anthony M Battram, PhD1,2*, Aina Oliver-Caldes, MD2,3*, Miquel Bosch i Crespo2,3*, Oriol Cardus, MSc2,3*, David F. Moreno, MD2,3*, Luis Gerardo Rodríguez-Lobato, MD, PhD2,3*, Alvaro Urbano-Ispizua, MD, PhD2,4,5,6 and Carlos Fernandez de Larrea, MD2,3,5

1Department of Hematology, Hospital Clínic de Barcelona, Barcelona, Spain
2Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
3Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clínic de Barcelona, Barcelona, Spain
4Institut Clinic de Malalties Hematologiques i Oncologiques (ICMHO), Hospital Clínic de Barcelona, Barcelona, Spain
5Department of Hematology, University of Barcelona, Barcelona, Spain
6Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain

5:30 PM

Reona Leo Sakemura, MD, PhD1,2, Claudia Manriquez-Roman1,2,3,4, Paulina Horvei, M.D.1*, Michelle J. Cox, Ph.D.1, Truc Huynh1*, James H. Girsch1,2,3,4*, Olivia Sirpilla, BS1,2,3,5, Kun Yun1,2,3,4, Carli M. Stewart, BS1,2,3,5, Ismail Can, PhD1,2,3,6, Ekene J. Ogbodo, Ph.D.1,2*, Mohamad M. Adada, M.D., Ph.D.1,2, Lionel A. Kankeu Fonkoua, M.D.1,2,7, Mehrdad Hefazi, M.D.1,2, Michael W. Ruff, M.D.1,8*, Kristina Ilieva-Babinski9*, Christian Augsberger9*, Maria Patra-Kneuer, Ph.D.9*, Christina Heitmüller, Ph.D.9*, Stefan Steidl, Ph.D.9*, Sameer A. Parikh, MD10, Wei Ding, MBBS, PhD2, Neil E. Kay, MD10, Grzegorz S. Nowakowski, MD2, Elizabeth L. Siegler, Ph.D.1,2* and Saad S. Kenderian, MD1,2,4,11

1T Cell Engineering, Mayo Clinic, Rochester, MN
2Division of Hematology, Mayo Clinic, Rochester, MN
3Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN
4Department of Molecular Medicine, Mayo Clinic, Rochester, MN
5Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN
6Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN
7Department of Oncology, Mayo Clinic, Rochester, MN
8Department of Neurology, Mayo Clinic, Rochester, MN
9MorphoSys AG, Planegg, Germany
10Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
11Department of Immunology, Mayo Clinic, Rochester, MN

5:45 PM

Hisashi Yano, MD1,2,3,4*, Takayuki Sato, PhD2,5*, Tokuyuki Shinohara, PhD2,5*, Keiko Koga, PhD2,5*, Shoichi Iriguchi, PhD2,3*, Atsushi Matsuda, PhD2,5*, Yasuyuki Miyake2,3*, Yoshiaki Kassai, PhD2,5*, Hitoshi Kiyoi4 and Shin Kaneko, MD, PhD2,3*

1Department of Hematology and Oncology, Japanese Red Cross Nagoya Daini Hospital, Nagoya-Shi, Japan
2Immune cell therapy project, Takeda-CiRA Joint Program for iPS Cell Applications (T-CiRA), Fujisawa-shi, Japan
3Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto-shi, Japan
4Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya-shi, Japan
5T-CiRA discovery, Takeda Pharmaceutical Company Limited, Fujisawa-shi, Japan

*signifies non-member of ASH